Figure 1
Figure 1. PARP1 inhibition suppresses and DNA-PKcs inhibition enhances chromosomal translocations. (A) The p5rE dual I-SceI translocation reporter system has 5′ and 3′ neo segments with splice donor (SD) and splice acceptor (SA) signals on chromosomes 14 and 17. After translocation NHEJ reconstitutes a functional neo on der[17], which can be quantified by clonal survival in G418. (B) p5rE cells were treated with the PARP1 inhibitor olaparib (3 μM), the DNA-PKcs inhibitor NU7441 (5 μM), or the DMSO vehicle as a control during and after translocation induction with I-SceI. Values are averages (± standard error of the mean [SEM]) for 3 or more determinations. (C) Olaparib does not alter expression of the transfected I-SceI. (D) NU7441 does not reduce survival duration of the p5rE cells, but olaparib decreases survival duration moderately. However, all results were normalized for survival in inhibitors.

PARP1 inhibition suppresses and DNA-PKcs inhibition enhances chromosomal translocations. (A) The p5rE dual I-SceI translocation reporter system has 5′ and 3′ neo segments with splice donor (SD) and splice acceptor (SA) signals on chromosomes 14 and 17. After translocation NHEJ reconstitutes a functional neo on der[17], which can be quantified by clonal survival in G418. (B) p5rE cells were treated with the PARP1 inhibitor olaparib (3 μM), the DNA-PKcs inhibitor NU7441 (5 μM), or the DMSO vehicle as a control during and after translocation induction with I-SceI. Values are averages (± standard error of the mean [SEM]) for 3 or more determinations. (C) Olaparib does not alter expression of the transfected I-SceI. (D) NU7441 does not reduce survival duration of the p5rE cells, but olaparib decreases survival duration moderately. However, all results were normalized for survival in inhibitors.

Close Modal

or Create an Account

Close Modal
Close Modal